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Two years after the publication of the 2013 guidelines for the management of arterial hypertension of the European 
Society of Hypertension (ESH) and the European Society of 
Cardiology (ESC),1 the ESH and the European Union Geriatric 
Medicine Society have created a common working group to 
examine the management of hypertensive subjects aged >80 
years. The general term hypertension in the elderly is not suf-
ficiently accurate because it mixes younger old patients (60–70 
years) with the oldest old. Our group believes that the man-
agement of hypertension in individuals aged ≥80 years should 
be specifically addressed. Although arbitrary, this cutoff value 
identifies a population that is expanding faster than any other 
age group with a 50% increase of life expectancy during the 
past 50 years2,3; furthermore, the incidence and prevalence of 
comorbidities, frailty, and loss of autonomy greatly increases 
after the age of 80 years4; finally, although there is limited evi-
dence on the management of hypertension in this age group, 
the latest clinical studies indicate that in these patients, treat-
ment may not be the same as in patients in the lower age strata.
The aim of this Working Group was to discuss more in-
depth treatment aspects of hypertensive patients aged ≥80 
years or older, with special focus on the difficulties and 
uncertainties posed by very old frail individuals. We focused, 
in particular, on the following points of the 2013 ESH/ESC 
guidelines:
Benefits of treatment.
Blood pressure (BP) thresholds and targets.
The choice of treatment.
Benefits of Treatment
The 2013 ESH/ESC guidelines1 reported the results of 
the Hypertension in the Very Elderly Double Blind Trial 
(HYVET). This showed that in hypertensive patients aged ≥80 
years, the administration of the thiazide-like diuretic indap-
amide supplemented, if necessary, by the angiotensin-convert-
ing enzyme inhibitor perindopril led to a significant reduction 
in the risk of major cardiovascular events and all-cause death 
when compared with placebo.2 From this, the guidelines con-
cluded that there is evidence that antihypertensive treatment is 
beneficial in octogenarians in whom BP is elevated and that, 
therefore, BP-lowering interventions can be strongly recom-
mended within this age range. However, both the ESH/ESC 
guidelines1 and other publications5–8 also point out limitations 
in the demonstration that treatment is beneficial in octogenar-
ians and this need to be addressed. First, the HYVET is to 
date the only randomized clinical trial that has addressed this 
important issue, making confirmation by a second trial highly 
desirable. Second, the age of the HYVET patients was for the 
most part closer to 80 years (73% in the 80–84 and 22% in the 
85–89 range), leaving the effect of treatment in patients close 
to or >90 years of age largely unexplored. Third, because the 
trial was prematurely interrupted by the Safety Monitoring 
Board (because of the evidence of protective effect of BP 
reduction in the treated group), the follow-up was rather 
short (median, 1.8 years). Despite the observation that in the 
HYVET patients the rate of events remained lower in the 
originally treated group 1 year after the trial termination,9 this 
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requires the duration of benefit to be determined. Finally, the 
2013 ESH/ESC guidelines state that the HYVET deliberately 
recruited patients in good physical and mental conditions and 
excluded ill and frail individuals, who are common among 
octogenarians, and also excluded patients with clinically rel-
evant orthostatic hypotension,1 thereby emphasizing probably 
the most important limitation of the available information, ie, 
leaving out of consideration the influence of patients’ general 
health, concomitant medication, and frailty on the decision 
about antihypertensive treatment implementation.
Post hoc analysis of the HYVET trial did not find a rela-
tionship between the benefit of antihypertensive treatment and 
patients’ frailty.10 This is reassuring for community-dwelling 
older hypertensives, but it is worth remembering that the 
HYVET did not include very frail patients and that patients 
with multiple morbidities and clinically significant cognitive 
impairment were also excluded. Indeed, both recent observa-
tional studies and registries show an important influence of the 
frailty status on the relationship between BP and outcomes, 
especially in treated hypertensives. This can be exemplified 
by studies that show the association between BP and mortality 
to vary according to the walking speed,11 cognitive function, 
assessed with the Mini Mental State Examination and dis-
ability, measured using the activity of daily living.12 Indeed, 
Odden et al11 showed that systolic BP in faster walkers was 
positively correlated with mortality, whereas no relationship 
between BP and mortality was observed among slower walk-
ers. Moreover, in patients unable to complete the walk test, BP 
was negatively associated with the risk of death.6 In the Milan 
Geriatrics study,12 higher systolic BP values were related to 
lower mortality among individuals aged ≥75 years who had 
an impaired Mini Mental State Examination (<25 points) or 
activity of daily living (<6 points). Also, the Predictive Value 
of Blood Pressure and Arterial Stiffness in Institutionalized 
Very Aged Population (PARTAGE) study has shown that what 
applies to middle-aged patients does not necessarily apply to 
old (≥80 years) nursing home residents,13–15 ie, the frailest old-
est patients. Actually, in this very old frail population, values 
of BP recorded with clinical standard procedures were similar 
to those obtained with multiple 3-day morning and evening 
measurements,13 and the negative relationship between the 
main end point of the study (total mortality and major cardio-
vascular events) and systolic BP (SBP) was observed with BP 
measured by a clinician, or self-measured.14 Interestingly, in 
this study, the highest mortality rate was observed in patients 
with SBP<130 mm Hg, who were treated with ≥2 antihyper-
tensive drugs, at variance from what was seen in those treated 
with 1 antihypertensive agent or not receiving any antihyper-
tensive drug at all.15 Likewise, Mossello et al16 found a more 
pronounced cognitive decline in treated old hypertensive 
patients having mild cognitive impairment or dementia in 
whom SBP was low (<128 mm Hg). Such an effect was not 
observed in subjects with low SBP but without antihyperten-
sive treatment.
It is important to remember that both low BP and ortho-
static hypotension are associated with syncope, falls, and 
related injuries and fractures.17–19 Therefore, both the ben-
efits (including preserving autonomy) and the risks of anti-
hypertensive therapy should be considered before starting 
treatment in the very frail older population. This population 
is the one at the highest risk of not only hypertension-related 
cardiovascular events but also hypotension-related events.19–21 
Hypotension-related events are likely to be more common in 
real life than in clinical trials in which treatment is delivered 
by expert physicians and patients are followed up closely. In 
a recent analysis of a large real-life database, very old indi-
viduals showed a significant increase in hospitalizations for 
hip fracture over the 30 days after initiation of antihyperten-
sive drug treatment.22 This has been previously observed in 
patients with a mean age of 80 years (between 86 and 100 
years; 26%) over the 45 days after antihypertensive treatment 
initiation.19
BP Thresholds and Targets
Because in the HYVET, patients were recruited if their entry 
SBP was ≥160 mm Hg, this is the SBP value recommended by 
the 2013 ESH/ESC guidelines at which drug treatment in octo-
genarians should be started.1 The threshold for treatment has 
been set at a lower SBP level (≥150 mm Hg) in the US 2014 
guidelines,5 but because octogenarians with entry SBP values 
<160 mm Hg have never been studied in randomized clinical 
trials or shown to have beneficial effects of BP-lowering inter-
ventions in subgroup data from trials addressing a larger age 
range, this does not seem to be based on solid evidence. Thus, 
it remains unsubstantiated whether in this very old patient cat-
egory grade 1 hypertension, ie, a SBP between 140 and 159 
mm Hg, might benefit from antihypertensive drugs.
Evidence on the BP goals for treatment in octogenarians 
is also limited. Both the 2013 ESH/ESC1 and the US guide-
lines5 recommend adopting the goal set by the HYVET, ie, 
<150 mm Hg SBP but neither addresses the question of the 
SBP value below which the treatment may interfere with 
patients’ safety. This is a critical issue because, as mentioned 
above, (1) observational studies have repeatedly shown that 
in the very old population, low BP values are associated with 
an increased morbidity and mortality, (2) somewhat statisti-
cally underpowered, randomized Japanese trials have not 
found clear benefits of SBP reductions <140 mmHg,23,24 and 
(3) a SBP reduction to <120, 130, or even 140 mm Hg may be 
associated with an increased risk of negative outcomes, ie, a 
J-curve phenomenon that seemed to be especially evident in 
frail individuals. Although the possibility of reverse causality 
(ie, greater initial risk as the cause of an excessive BP fall 
and increased outcomes) cannot be excluded, a pathophysi-
ologically founded hypothesis is that in frail very old subjects, 
an impairment of the mechanisms preserving perfusion might 
critically decrease blood flow to vital organs (heart, brain, 
and kidney).21 This is at variance from healthier old individu-
als in whom no clear negative influence of BP decrease on 
vital organ perfusion and associated complications has been 
reported.25,26 Therefore, the following multiple questions still 
remain open. Do frail very old hypertensives get benefits from 
antihypertensive treatment? Is the benefit similar or different 
in nonfrail and frail individuals? Should the BP threshold at 
which to start treatment be higher as recently recommended 
by guidelines? Which are the BP targets that maximize pro-
tection in frail very old patients, without posing a risk to their 
safety?
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The recently published Systolic Blood Pressure 
Intervention Trial (SPRINT)27 shows that among patients at 
high cardiovascular risk and already using antihypertensive 
drugs targeting a SBP of 120 mm Hg resulted in lower inci-
dence of major cardiovascular events and death from any 
cause when compared with patients targeting a SBP of 140 
mm Hg; this result was also statistically significant in the sub-
group (28% of all) of patients aged >75 years. However, in 
the SPRINT, the number of patients aged ≥80 years has not 
been reported and may be substantially lower than the 28% 
(2600) patients aged ≥75 years. Furthermore, interpretation of 
several aspects of the SPRINT data (lack of beneficial effect 
on stroke, masking effect of diuretics on signs and symptoms 
of >3 drug heart failure, BP measuring approach, etc) are still 
under discussion.28,29 Finally, and more importantly, patients 
with advanced frailty, cognitive decline, loss of autonomy, and 
living in nursing home were excluded from the trial. Exclusion 
from trial extended to patients with decompensated heart fail-
ure, history of stroke, and diabetes mellitus, ie, conditions 
commonly associated with hypertension in aged individuals 
in whom they represent a common cause of death. This is a 
crucial issue also because in SPRINT, the aggressively treated 
group showed a substantial increase of hypotension, syncope, 
electrolyte abnormalities, and renal failure, ie, adverse reac-
tions that are likely to be magnified in very old patients, even 
more so if frail. Thus, application of the SPRINT results in 
this population cannot be done unconditionally, also consider-
ing that other studies including frail people have not obtained 
similar results. Although potentially useful to robust old 
hypertensives, these results may have a limited transferabil-
ity to frail, very old patients in whom the treatment strategies 
and the treatment goals should be largely driven by their func-
tional status and comorbidities.
Choice of Treatment
On the basis of trials performed in patients aged ≥60 years, 
both the 2013 ESH/ESC1 guidelines and the US guidelines2 
recommend that the antihypertensive treatment to be imple-
mented in old hypertensive subjects to use the same drug 
classes that are recommended for younger patients, ie, diuret-
ics, angiotensin receptor antagonists, angiotensin-converting 
enzyme inhibitors, and calcium channel blockers, with an 
extension to β-blockers in the ESH/ESC guidelines.1 On the 
basis of large meta-analyses, they also consider the above 5 
classes similarly protective in old hypertensive individuals 
although indicating diuretics and calcium channel blockers as 
the preferred choice in isolated systolic hypertension given the 
preferential use of these 2 drugs in trials on this condition. 
Neither the European nor the US guidelines mention any dif-
ference in the type of treatment in hypertensive patients aged 
≥80 years when compared with patients aged <80 years. In the 
HYVET, the drugs used were the thiazide-like diuretic indap-
amide complemented by perindopril in ≈70% of the patients, 
suggesting a possible preference for a treatment based on a 
diuretic-angiotensin-converting enzyme inhibitor combi-
nation. However, in a prespecified secondary analysis of a 
Japanese study30 on hypertensive patients aged 75 to 84 years, 
those receiving an angiotensin receptor antagonist/calcium 
channel blocker combination showed a reduction in the risk of 
stroke when compared with patients receiving an angiotensin 
receptor antagonist/diuretic combination. Given the evidence 
that the benefit of treatment largely depends on BP lowering 
per se,31 ie, regardless how it is obtained, the opinion of this 
Working Group is that in principle the large number of antihy-
pertensive drug classes recommended for younger age strata 
are suitable for use also in the oldest-old individuals. Except 
when required for specific clinical conditions (eg, angina pec-
toris, previous myocardial infarction, and heart failure), the 
use of β-blockers in these very old hypertensive individuals 
remains controversial, however.32,33
In the 2013 ESH/ESC guidelines,1 the suggestion is made 
to consider initiation of antihypertensive treatment with a 
2-drug combination if cardiovascular risk is high, with no 
distinction between younger and older patients. However, 
in octogenarians, initial administration of 2 antihypertensive 
drugs, even when administered at low doses, may put subjects 
at an unwarranted risk of hypotension, given that homeostatic 
mechanisms that maintain BP against gravity and other chal-
lenges undergo a progressive impairment as age advances.34 
Furthermore, increasing the number of the prescribed drugs 
may increase the probability of adverse drug, drug–drug, and 
drug–disease reactions and interactions in patients in whom 
polypharmacy is extremely common because of the frequent 
concomitance of both cardiovascular and noncardiovascular 
diseases.35,36 Finally, an increased number of prescribed drugs 
is known to have a negative effect on adherence to treat-
ment, an especially serious problem in very old patients in 
whom adherence (and errors in taking the prescribed medi-
cines) may be adversely affected by cognitive dysfunction 
and dementia.37 Combination of 2 antihypertensive drugs 
should be considered if monotherapy fails to control BP, but 
only if consideration of the potential protective effect of BP 
reduction versus the risk of hypotension and other adverse 
effects makes a benefit likely. As already mentioned in the 
2013 ESH/ESC1 and other guidelines,8 antihypertensive treat-
ment in octogenarians should in general not exceed 3 differ-
ent medications, unless BP remains severely uncontrolled, or 
patients become 80 under an earlier initiated >3 drug regime, 
but still well-tolerated, treatment. Under these circumstances, 
however, patients’ follow-up should be intensified because a 
large body of evidence shows that drug–drug interactions 
and other iatrogenic problems dramatically increase with an 
increase in the number of administered drugs and more so in 
frail patients38
Suggestions of the Working Group for the 
Management of Hypertension in Octogenarians
Based on the above comments, we propose the following:
Treatment Initiation
The 2013 ESH/ESC guidelines state that in individuals aged 
≥80 years with an initial SBP≥160 mm Hg, SBP should be 
reduced by drug treatment provided that patients are in good 
physical and mental conditions. We believe that this recom-
mendation should be accompanied by (1) a more precise defi-
nition of the meaning of the term good physical and mental 
conditions and (2) an indication of how physical conditions, 
mental conditions, and the frailty status can be assessed.
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A rapid (<10 minutes) assessment of frailty is feasible. 
The most frequently used is the Fried frailty phenotype39 in 
which frailty is defined by the presence of at least 3 of the 
following: weight loss, exhaustion, weakness, decreased gait 
speed, and diminished physical activity. Other scales used in 
different countries40–42 may also be referred to.
The ESH/ESC guidelines also state, that continuation of 
a well-tolerated antihypertensive treatment should be consid-
ered when a treated individual becomes octogenarian. This is 
a reasonable recommendation, but we suggest that in this case, 
physicians are advised to monitor the frailty status to detect 
when a change in treatment strategy may be needed.
Treatment Goals
The 2013 ESH/ESC guidelines recommend treatment to lower 
SBP to <150 mm Hg in octogenarians in good physical and 
mental conditions We believe that this might be usefully com-
plemented by mentioning that, while keeping <150 mm Hg SBP 
as the evidence-based target, for safety reasons antihypertensive 
drugs should be reduced or even stopped if SBP is lowered to 
<130 mm Hg, thus keeping the 150 to 130 mm Hg on-treatment 
SBP values as a safety range. Self-assessment of BP at home and 
if necessary 24-hour ambulatory BP measurements can contrib-
ute to identify treated patients with too low BP levels. Some con-
sideration should also be given to the assessment of subclinical 
organ damage, in particular, left ventricular systolic and diastolic 
dysfunction as well as arterial stiffness. However, the question is 
raised about the prognostic significance of these parameters in 
older hypertensives, and whether their improvement would actu-
ally translate into an improvement in mortality in the elderly.43 
It should be emphasized that nearly all guidelines on BP targets 
refer to office BP values because no outcome trial has addressed 
the optimal out-of-office BP target in older or younger hyper-
tensive patient strata. To date, what has been established is that 
(1) office BP is higher than 24-hour mean or home BP44 and (2) 
this discrepancy decreases progressively as office BP decreases. 
This suggests that these values do not differ substantially in indi-
viduals with office BP controlled,45 a possibility, however, that 
needs to be tested by randomized trials.
Choice of Antihypertensive Drugs
The 2013 ESH/ESC guidelines1 recommend all 5 major anti-
hypertensive drug classes (with a preference for diuretics and 
calcium channel blockers in isolated systolic hypertension) for 
use in old hypertensive subjects, with no distinction between 
those aged above or below 80 years. We suggest that a dis-
tinction should be made and that, based on the HYVET, in 
octogenarians, angiotensin-converting enzyme inhibitors and 
thiazide-like diuretics should be positioned at the same level 
as calcium channel blockers. The working group thinks that 
despite the age-related high cardiovascular risk, initial high 
dose or combination of treatment should not be encouraged, 
and that combination of treatment should only be considered 
after failure of initial low-dose therapy.
Frail Very Old Patients (People Living in Nursing Homes 
or Needing Assistance on a Daily Basis for Their Basic 
Activities)
The 2013 ESH/ESC guidelines state that “in frail older patients, 
it is recommended to leave decisions on antihypertensive 
therapy to the treating physician, and base them on monitoring 
of the clinical effects of treatment.” We suggest that in these 
patients, therapeutic decisions should be preceded by (1) accu-
rate information on their functional capacity, cognitive status. 
Although notoriously difficult, an estimate of patient’s prog-
nosis should also be attempted; (2) attention to multiple drug 
administration so common in this age stratum; (3) stratifica-
tion of the frailty status by one of the available rapid methods; 
and (4) identification and correction of factors that predispose 
to an excessive BP reduction, orthostatic hypotension, and 
other hypotensive episodes, such as concomitant treatments, 
malnutrition, and dehydration. The decision of the practicing 
physician to start treatment in a frail very old patient should 
be especially cautious (low drug doses and monotherapy) and 
patient status should be checked on a frequent basis.
It is obvious that the recommendations of our group per-
tain mainly to very old people (ie, ≥80 years) with frailty. 
However, we believe that an individual in his late sixties or 
early seventies who expresses the condition of frailty—and in 
whom at that moment a difference between the calendar and 
the biological age becomes apparent—should be approached 
in a similar way. Because prevalence of frailty dramatically 
increases with increasing age,46 the latter situation, however, 
would take place in few cases. For this reason, a systematic 
screening for frailty, which we propose for very old people, 
might take place in their younger counterparts only when a 
clinical and functional problems become imminent.
Finally, we would like to point out that research based on 
not only registries, administrative databases but also interven-
tional controlled trials should be favored to assess the ben-
efits/risks ratio of multidrug antihypertensive treatment in the 
growing population of very old frail patients.
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